Merck (MRK) Animal Health, a division of Merck & Co., announced the U.S. Food and Drug Administration has granted a conditional approval for EXZOLT CATTLE-CA1. This innovative product is in the newest class of parasiticides known as isoxazolines. The pour-on solution is effective for the prevention and treatment of infestations caused by New World screwworm larvae. It is also conditionally approved for the treatment and control of cattle fever tick. EXZOLT CATTLE-CA1 was granted conditional approval based on demonstration of safety and a reasonable expectation of effectiveness when administered according to label directions based on global studies conducted by Merck Animal Health in recent years. EXZOLT CATTLE-CA1 is conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-617. EXZOLT CATTLE-CA1 will be available by prescription in 1 L or 5 L presentations in the first quarter of 2026.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- FDA shift in drug study requirements sends trial runners lower
- FDA to reduce number of trials required for drug approvals, STAT reports
- Merck price target raised to $120 from $105 at Scotiabank
- Is AstraZeneca’s Stock (AZN) a Good Investment Right Now?
- Top drug regulator Richard Pazdur preparing to exit FDA, STAT News reports